This database contains 203 studies, archived under the term: "Methods"
Click here to filter this large number of results.
Alzheimer’s disease: is pacemaker implantation safe?
Osmonov, Damirbek,
Ozcan, Kazim Serhan,
Altay, Servet,
Erdinler, Izzet,
Yildirim, Ersin,
Türkkan, Ceyhan,
Canga, Yigit,
Alper, Ahmet Taha,
Cakmak, Nazmiye,
Gürkan, Kadir
Aim: To evaluate the safety of pacemaker implantation in patients with Alzheimer’s disease (AD).; Methods: We reviewed all cases admitted to our institution between January 2008 and June 2009, with symptomatic bradyarrhythmia for whom a permanent pacemaker was implanted. Beginning in June 2009, we prospectively collected data from all patients with the same diagnosis and […]
Dementia care in the general practice setting: a cluster randomized trial on the effectiveness and cost impact of three management strategies
Menn, Petra,
Holle, Rolf,
Kunz, Simone,
Donath, Carolin,
Lauterberg, Jörg,
Leidl, Reiner,
Marx, Peter,
Mehlig, Hilmar,
Ruckdäschel, Stephan,
Vollmar, Horst Christian,
Wunder, Sonja,
Gräßel, Elmar
Objective: To compare a complex nondrug intervention including actively approaching counseling and caregiver support groups with differing intensity against usual care with respect to time to institutionalization in patients with dementia.; Methods: Within this three-armed cluster-randomized controlled trial, 390 community-dwelling patients aged 65 years or older with physician-diagnosed mild to moderate dementia and their caregivers […]
Memory and communication support strategies in dementia: effect of a training program for informal caregivers
Liddle, Jacki,
Smith-Conway, Erin R.,
Baker, Rosemary,
Angwin, Anthony J.,
Gallois, Cindy,
Copland, David A.,
Pachana, Nancy A.,
Humphreys, Michael S.,
Byrne, Gerard J.,
Chenery, Helen J.
Background: People with dementia have a range of needs that are met by informal caregivers. A DVD-based training program was developed using research-based strategies for memory and communication in dementia. The effectiveness of the training on the caregiver experience and the well-being of the person with dementia was evaluated.; Methods: A pre-test/post-test controlled trial was […]
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT
Kimura, Noriyuki,
Kumamoto, Toshihide,
Masuda, Teruaki,
Hanaoka, Takuya,
Okazaki, Toshio,
Arakawa, Ryuki
Background: We attempt to evaluate objectively the regional cerebral blood flow (rCBF) changes during long-term donepezil therapy and the relationship between the clinical response and rCBF change in patients with Alzheimer’s disease (AD).; Patients and Methods: Thirty-one patients with mild-to-moderate AD (11 men, 20 female; mean age, 76.2 ± 6.7 years) were treated with donepezil […]
Predictors of acceptance of offered care management intervention services in a quality improvement trial for dementia
Kaisey, Marwa,
Mittman, Brian,
Pearson, Marjorie,
Connor, Karen I.,
Chodosh, Joshua,
Vassar, Stefanie D.,
Nguyen, France T.,
Vickrey, Barbara G.
Objective: Care management approaches have been proven to improve outcomes for patients with dementia and their family caregivers (dyads). However, acceptance of services in these programs is incomplete, impacting effectiveness. Acceptance may be related to dyad as well as healthcare system characteristics, but knowledge about factors associated with program acceptance is lacking. This study investigates […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]